Home
Drugs
Venetoclax
Clinical Trials

Clinical Trials Related to Venetoclax

Related studies linked through entity extraction aliases.

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Status: RECRUITING
Phase: PHASE2

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Status: RECRUITING
Phase: PHASE1/PHASE2

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Status: RECRUITING
Phase: PHASE2

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Status: TERMINATED
Phase: PHASE1/PHASE2

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Status: RECRUITING
Phase: PHASE1

Real World Outcomes Using Novel Agents for AML in the UK

Status: UNKNOWN
Phase: N/A

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Status: RECRUITING
Phase: PHASE1

CC-486 and Venetoclax for Acute Myeloid Leukemia

Status: RECRUITING
Phase: PHASE1

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Status: TERMINATED
Phase: PHASE1

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Status: TERMINATED
Phase: PHASE2

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status: SUSPENDED
Phase: PHASE1

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Status: UNKNOWN
Phase: NA

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

Status: NO_LONGER_AVAILABLE
Phase: N/A

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status: RECRUITING
Phase: PHASE1/PHASE2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Status: WITHDRAWN
Phase: PHASE2

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Status: RECRUITING
Phase: PHASE3

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2